DCF Valuation
Silence Therapeutics PLC (SLN) DCF Valuation — Is SLN overvalued?
The estimated DCF fair value of one Silence Therapeutics PLC (SLN) share is $1.77. Compared to the current market price of $11.24, the stock is overvalued by 84.3%.
DCF fair value
$1.77
Market price
$11.24
Upside / downside
−84.3%
Silence Therapeutics PLC (SLN) DCF valuation FAQ
What is the DCF fair value of Silence Therapeutics PLC (SLN)?
The discounted-cash-flow model estimates the intrinsic fair value of one Silence Therapeutics PLC (SLN) share at $1.77, based on a 10-year projection of its cash flows converging to Damodaran industry averages.
Is Silence Therapeutics PLC (SLN) overvalued or undervalued?
Against the current market price of $11.24, the DCF fair value of $1.77 implies SLN is overvalued by 84.3%.
How is the SLN DCF value calculated?
It is a 10-year discounted-cash-flow estimate built from Silence Therapeutics PLC's reported fundamentals, with terminal assumptions anchored to Damodaran NYU industry datasets. The market price refreshes daily; the DCF fair value updates when Silence Therapeutics PLC files a new quarterly or annual report.
How this SLN valuation is built
The model projects ten years of Silence Therapeutics PLC's free cash flow to the firm and discounts each year at its own cost of capital. Rather than assuming today's growth and margins persist forever, a moat-scoring step — weighing Silence Therapeutics PLC's ROIC-versus-WACC spread, gross-margin trend, and reinvestment efficiency — decides how many years the business holds its edge before its economics mean-revert toward the Damodaran NYU benchmarks for its industry.
WACC is rebuilt each year from an unlevered-then-relevered beta and the company's evolving capital structure; terminal value uses the Gordon growth model with a reinvestment rate tied to the return earned on new capital (goodwill stripped out to reflect operating efficiency). Every assumption — growth, margins, tax, leverage, convergence timing — is editable, and running the full interactive model adds a 10,000-draw Monte Carlo simulation and WACC-versus-terminal-growth sensitivity heatmaps.
The market price refreshes daily; the DCF fair value updates when Silence Therapeutics PLC files a new quarterly or annual report. For educational/informational purposes only — not investment advice. Last updated 2026-08-06.